Frankfurt - Delayed Quote EUR

Akeso, Inc. (4RY.F)

9.40
+0.05
+(0.53%)
At close: May 16 at 7:07:06 PM GMT+2
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
2,123,944
2,123,944
4,526,253
837,656
225,626
Cost of Revenue
289,042
289,042
133,248
94,117
31,259
Gross Profit
1,834,902
1,834,902
4,393,005
743,539
194,367
Operating Expense
2,338,841
2,338,841
2,226,181
1,965,561
1,460,801
Operating Income
-503,939
-503,939
2,166,824
-1,222,022
-1,266,434
Net Non Operating Interest Income Expense
138,121
138,121
32,746
-21,318
3,884
Pretax Income
-501,093
-501,093
1,942,525
-1,422,216
-1,258,126
Tax Provision
0
0
174
0
0
Net Income Common Stockholders
-514,515
-514,515
2,028,300
-1,168,393
-1,074,933
Diluted NI Available to Com Stockholders
-514,515
-514,515
2,028,300
-1,168,393
-1,074,933
Basic EPS
-0.60
-0.60
2.42
-1.42
-1.32
Diluted EPS
-0.60
-0.60
2.42
-1.42
-1.32
Basic Average Shares
851,026.46
851,026.46
837,683.78
824,989.86
815,931.80
Diluted Average Shares
851,026.46
851,026.46
837,821.48
824,989.86
815,931.80
Rent Expense Supplemental
2,902
2,902
2,554
--
--
Total Expenses
2,627,883
2,627,883
2,359,429
2,059,678
1,492,060
Net Income from Continuing & Discontinued Operation
-514,515
-514,515
2,028,300
-1,168,393
-1,074,933
Normalized Income
-542,124
-542,124
1,980,352.30
-1,174,497
-1,083,455
Interest Income
206,381
206,381
119,733
21,972
14,236
Interest Expense
68,260
68,260
86,987
43,290
10,352
Net Interest Income
138,121
138,121
32,746
-21,318
3,884
EBIT
-432,833
-432,833
2,029,512
-1,378,926
-1,247,774
EBITDA
-238,865
-238,865
2,172,280
-1,273,137
-1,189,531
Reconciled Cost of Revenue
289,042
289,042
133,248
94,117
31,259
Reconciled Depreciation
193,968
193,968
142,768
105,789
58,243
Net Income from Continuing Operation Net Minority Interest
-514,515
-514,515
2,028,300
-1,168,393
-1,074,933
Total Unusual Items Excluding Goodwill
27,609
27,609
47,952
6,104
8,522
Total Unusual Items
27,609
27,609
47,952
6,104
8,522
Normalized EBITDA
-266,474
-266,474
2,124,328
-1,279,241
-1,198,053
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
4.30
0
0
12/31/2021 - 4/28/2020

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

WINTW WINDTREE THERAPEUTICS INC C/WTS
0.0060
+445.45%
 
AAPG Ascentage Pharma Group Internat
22.65
+0.13%
 
ADAG Adagene Inc.
1.7700
-2.75%
 
ACTU Actuate Therapeutics, Inc. Common stock
10.55
+8.09%
 
1801.HK INNOVENT BIO
51.000
+2.10%
 
ADIL Adial Pharmaceuticals, Inc.
0.6578
-0.33%
 
ACXP Acurx Pharmaceuticals, Inc.
0.3870
+3.73%
 
ACLX Arcellx, Inc.
58.78
+0.56%
 
TRVI Trevi Therapeutics, Inc.
6.50
+5.01%
 
ACRS Aclaris Therapeutics, Inc.
1.3100
+7.38%